Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Weinstock

Showing results (71-80 of 172) with videos related to

Pageof 18
Sort By:
Oncogene|November 28, 2020
RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemiaDavid Koschut, Debleena Ray, Zhenhua Li, et al.
Blood|December 15, 2018
Bruton tyrosine kinase degradation as a therapeutic strategy for cancerDennis Dobrovolsky, Eric S Wang, Sara Morrow, et al.
Cell Chemical Biology|April 4, 2023
ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomasBaishan Jiang, David M Weinstock, Katherine A Donovan, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 20, 2020
Polymerase δ promotes chromosomal rearrangements and imprecise double-strand break repairJacob V Layer, Lydie Debaize, Alexandria Van Scoyk, et al.
Nature Genetics|November 22, 2016
Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex biasAndrew Dunford, David M Weinstock, Virginia Savova, et al.
Cancer Research|June 13, 2012
BCL2 suppresses PARP1 function and nonapoptotic cell deathChaitali Dutta, Tovah Day, Nadja Kopp, et al.
Blood|March 28, 2015
A roadmap for discovery and translation in lymphomaDavid M Weinstock, Riccardo Dalla-Favera, Randy D Gascoyne, et al.
Blood|August 10, 2018
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomasIrene Scarfò, Maria Ormhøj, Matthew J Frigault, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic LeukemiaYana Pikman, Gabriela Alexe, Giovanni Roti, et al.
Journal of Hematology & Oncology|July 18, 2020
DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomasYonghan He, Raphael Koch, Vivekananda Budamagunta, et al.
Pageof 18

Showing results (71-80 of 172) with videos related to

Sort By:
Pageof 18
Oncogene|November 28, 2020
RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemiaDavid Koschut, Debleena Ray, Zhenhua Li, et al.
Blood|December 15, 2018
Bruton tyrosine kinase degradation as a therapeutic strategy for cancerDennis Dobrovolsky, Eric S Wang, Sara Morrow, et al.
Cell Chemical Biology|April 4, 2023
ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomasBaishan Jiang, David M Weinstock, Katherine A Donovan, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 20, 2020
Polymerase δ promotes chromosomal rearrangements and imprecise double-strand break repairJacob V Layer, Lydie Debaize, Alexandria Van Scoyk, et al.
Nature Genetics|November 22, 2016
Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex biasAndrew Dunford, David M Weinstock, Virginia Savova, et al.
Cancer Research|June 13, 2012
BCL2 suppresses PARP1 function and nonapoptotic cell deathChaitali Dutta, Tovah Day, Nadja Kopp, et al.
Blood|March 28, 2015
A roadmap for discovery and translation in lymphomaDavid M Weinstock, Riccardo Dalla-Favera, Randy D Gascoyne, et al.
Blood|August 10, 2018
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomasIrene Scarfò, Maria Ormhøj, Matthew J Frigault, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic LeukemiaYana Pikman, Gabriela Alexe, Giovanni Roti, et al.
Journal of Hematology & Oncology|July 18, 2020
DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomasYonghan He, Raphael Koch, Vivekananda Budamagunta, et al.
Pageof 18